XenoPort to Present at the Morgan Stanley Global Healthcare Conference
Morgan Stanley Global Healthcare Conference 2013
SANTA CLARA, Calif. -- September 3, 2013
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via
the World Wide Web to its presentation at the Morgan Stanley Global Healthcare
Conference. The live presentation will occur at 8:10 a.m. Pacific Time (11:10
a.m. Eastern Time) on Wednesday, September 11, 2013. A replay of the
presentation will also be available.
To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Website at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may be
necessary to listen to the Webcast.
A replay of the Webcast can be accessed for a minimum of one month and will be
available approximately 24 hours after the live presentation.
XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. XenoPort is currently
commercializing Horizant^® (gabapentin enacarbil) Extended-Release Tablets,
its first approved product in the United States, and developing a novel
fumaric acid ester product candidate, XP23829, as a potential treatment for
relapsing-remitting multiple sclerosis and/or psoriasis. Regnite^® (gabapentin
enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas
Pharma Inc. XenoPort holds all other world-wide rights to gabapentin
enacarbil. XenoPort's pipeline of product candidates also includes potential
treatments for patients with spasticity related to spinal cord injury and
To learn more about XenoPort, please visit the Website at www.XenoPort.com.
Horizant, Regnite and XENOPORT are registered trademarks of XenoPort, Inc.
Jackie Cossmon, 408-616-7220
Press spacebar to pause and continue. Press esc to stop.